Home/Filings/4/0001870913-24-000018
4//SEC Filing

Shanmugam Muthusamy 4

Accession 0001870913-24-000018

CIK 0001023024other

Filed

May 16, 8:00 PM ET

Accepted

May 17, 6:05 PM ET

Size

10.6 KB

Accession

0001870913-24-000018

Insider Transaction Report

Form 4
Period: 2024-05-15
Shanmugam Muthusamy
DirectorHEAD OF R&D, COO-NOVITIUM OPS
Transactions
  • Sale

    Common Stock

    2024-05-15$65.86/sh14,850$978,021767,770 total(indirect: By LLC)
  • Sale

    Common Stock

    2024-05-16$63.84/sh16,459$1,050,743751,311 total(indirect: By LLC)
  • Sale

    Common Stock

    2024-05-17$62.09/sh5,836$362,357745,475 total(indirect: By LLC)
Holdings
  • Common Stock

    68,652
  • Common Stock

    (indirect: By LLC)
    5,000
Footnotes (6)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.
  • [F2]The shares were sold in multiple trades at prices ranging from $64.66 to $66.54. The price reported above reflects the weighted average sales price.
  • [F3]The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
  • [F4]The shares were sold in multiple trades at prices ranging from $63.28 to $64.90. The price reported above reflects the weighted average sales price.
  • [F5]The shares were sold in multiple trades at prices ranging from $61.43 to $64.00. The price reported above reflects the weighted average sales price.
  • [F6]The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Issuer

ANI PHARMACEUTICALS INC

CIK 0001023024

Entity typeother

Related Parties

1
  • filerCIK 0001870913

Filing Metadata

Form type
4
Filed
May 16, 8:00 PM ET
Accepted
May 17, 6:05 PM ET
Size
10.6 KB